Dec. 9, 2013 10:00 UTC

Mazor Robotics Expands its Foothold in North America

Hospital in the Southeastern United States Purchases Renaissance System

CAESAREA, Israel--(BUSINESS WIRE)-- Mazor Robotics Ltd. (TASE: MZOR; NASDAQCM: MZOR), the developer of Renaissance™, an innovative surgical guidance system and its complementary products, announced today that a hospital in the southeastern United States has purchased its first Renaissance system. The hospital that purchased the system is an integrated healthcare delivery system that provides care from birth to hospice and for more than 90 years has earned a reputation for technological excellence throughout the Southeast.

“We are excited from the continued adoption of the Mazor Robotics Renaissance system by spine surgeons and health providers in the United States and particularly in the south east of the United States,” commented Ori Hadomi, Chief Executive Officer, “There are now 11 Renaissance systems in the Southeastern United States providing surgeons and their patients a highly accurate and safe approach to spine surgery.”

About Mazor

Mazor Robotics (TASE: MZOR; NASDAQCM: MZOR) is dedicated to the development and marketing of innovative surgical robots and complementary products that provide a safer surgical environment for patients, surgeons, and operating room staff. Mazor Robotics’ flagship product, Renaissance™, is a state-of-the-art surgical robotic system that enables surgeons to conduct spine surgeries in an accurate and secure manner. Mazor Robotics systems have been successfully used in the placement of over 35,000 implants worldwide. Numerous peer-reviewed publications and presentations at leading scientific conferences have validated the accuracy, usability, and clinical advantages of Mazor Robotics technology. For more information, the content of which is not part of this press release, please visit www.mazorrobotics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the clinical and economic benefits of Renaissance, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor's current expectations and projections about future events. There are important factors that could cause Mazor's actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor's filings with the Securities and Exchange Commission (SEC)., including those discussed under the heading "Risk Factors" in Mazor’s registration statement on Form F-1 and in subsequent filings with the SEC. For more details, refer to Mazor's SEC filings and the amendments thereto. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.

Contacts

EVC Group
Investors:
Michael Polyviou, 212-850-6020
mpolyviou@evcgroup.com
or
Robert Jones, 646-201-5447
bjones@evcgroup.com
or
Media:
John Carter, 212-850-6021
jcarter@evcgroup.com


Source: Mazor Robotics Ltd.